Regulatory Approval

Jazz Pharma's lung cancer drug Zepzelca fails a key trial, raising regulatory questions. Yet its strength in another setting reveals a complex drug development system.

With Bill C-34, Canada wants to make social media and AI safer for children. But can it balance protection with privacy and digital freedom?

Ottawa's new Safe Social Media Act imposes strict duties on tech giants to protect children, but raises critical questions about privacy and digital freedom.

As youth nicotine pouch use soars, Imperial Tobacco Canada calls for a crackdown on illicit sales. But is this a genuine public health plea or a masterful play to secure its market?

Ottawa’s new Safe Social Media Act is more than a child safety law; it's a high-stakes stress test for Big Tech's business models and a new front in the global war on digital risk.

With over 55,000 on waitlists for the UK's first oral weight-loss pill, the market is set to explode. But strict rules and high hopes face a reality check.

Bill C-34 aims to shield kids from online harms, but health advocates see a bigger prize: curbing the digital marketing of unhealthy products.

A projected 14.9% CAGR signals a gold rush in Alzheimer's agitation treatment. New, safer drugs are replacing risky antipsychotics, offering hope to millions.

For 17 years, Jeffrey Phillips helped California revoke professional licenses. Now, he's joined the defense. His move reveals a crucial shift in the high-stakes world of regulatory law.

A new FDA-approved therapy from Boehringer Ingelheim and a liquid biopsy from Guardant Health offer the first targeted initial treatment for HER2-mutant NSCLC.

Co-Diagnostics leverages its COVID-19 success for a strategic push into Latin America, aiming to bring rapid PCR testing for a host of diseases to Mexico.

For millions, the 'why' behind infertility remains a mystery. New genomic mapping tech is finally providing answers, changing the landscape of family planning.

A new report reveals vulnerability growth is outpacing enterprise defenses, shrinking response times to hours. This isn't just an IT issue—it's a boardroom crisis.

Spain's Cecabank, with crypto-native Bit2Me, launches a MiCA-compliant custody service, bringing banks like Renta 4 into the digital asset era.

Hainan's new medical tourism hub is more than a hospital—it's a strategic play for global dominance, using exclusive drugs and VIP service to lure patients.

Canada Nickel secures C$6.2M for its 'NetZero Nickel' vision, but a steep 15% interest rate on a major loan reveals the high cost of its green ambitions.

CME Group and Morningstar have forged an exclusive deal, turning a $3 trillion asset base into a new battlefield for equity derivatives and risk management.

Ridgewood Infrastructure's acquisition of Dauntless Air isn't just a deal; it's a bet on a new class of essential assets fueled by climate change and tech.

Frasers Group's €1.98 billion offer for Hugo Boss is more than a deal; it's a strategic gambit that tests the value of a legacy German brand.

A new platform signals a major shift, turning the chaotic maze of ESG rules into a strategic playbook for product companies. Is this the future of compliance?